Western Australia Asbestos Review Program
Western Australia Asbestos Review Program: medical follow up of West Australians exposed to asbestos
Sir Charles Gairdner Hospital
6,000 participants
Feb 1, 1990
Observational
Conditions
Summary
This is a longitudinal observational study that will monitor the health of Western Australians who have been exposed to asbestos through an annual clinical review. Who is it for? You may be eligible for this study if you are a resident of Western Australia aged 16 years or older, you are an asbestos exposed ex-worker and/or ex-resident of Wittenoom (the asbestos mine), or if you are an individual with more than 3 months cumulative asbestos exposure and/or radiological evidence of asbestos related disease. Study details All participants who choose to enrol in this study will be asked to undergo a general and lung health assessment, lung function tests and an ultra-low dose CT scan of the chest to look for lung disease from asbestos. The Western Australian Asbestos Review Program (ARP) also performs blood tests to see if we can find markers of lung disease to help diagnose problems earlier. Each of these investigations will be completed annually, the appointment usually takes about two hours. The ARP has no limit on age or how long it is since first exposure to asbestos – the study aims to follow as many people exposed to asbestos for as long as possible. It is hoped this research will provide important information that will allow clinicians to further characterise, diagnose and understand asbestos-related diseases. This information may then be used to improve health outcomes of future patients who have been affected by asbestos exposure.
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A two hour annual review at of persons exposed to asbestos during work or otherwise including general health and specific respiratory questionnaire, blood draw for biomarkers and DNA and lung function followed by ultra-low dose computed tomography (CT) imaging of the chest. Anticipated duration of follow annual up is up to 30 years although participants may choose to continue after this time. Annual reviews and prospective data collection have occured since 1990. There is no retrospective data collection.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621001627842